Alnylam Pharmace. buy Commando
Start price
20.08.22
/
50%
€214.90
Target price
20.08.23
-
Performance (%)
-14.30%
End price
07.03.23
€184.16
Summary
This prediction ended on 07.03.23 with a price of €184.16. The prediction for Alnylam Pharmace. disappointed with a performance of -14.30%. Commando has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | 2.595% | 2.595% | -11.420% | 37.852% |
| iShares Core DAX® | 2.992% | 3.220% | 4.271% | 53.697% |
| iShares Nasdaq 100 | -1.584% | -3.172% | 24.749% | 76.697% |
| iShares Nikkei 225® | -2.254% | -9.924% | 43.518% | 60.793% |
| iShares S&P 500 | -0.009% | 1.641% | 20.967% | 62.807% |
Comments by Commando for this prediction
In the thread Alnylam Pharmace. diskutieren
Buy Alnylam Pharmace.